Bridge Biotherapeutics Receives FDA Authorization to Proceed with the First-in-Human Study of BBT-207, a 4th generation EGFR TKI

The company has been notified by the FDA that the Phase 1/2 clinical trial may proceed The latest preclinical data explored the antitumor efficacy and the intracranial activity of BBT-207 SEONGNAM, South Korea and CAMBRIDGE, Mass., April 23, 2023 /PRNewswire/ — Bridge Biotherapeutics…